GlassScriptPhysician profile
Bryna M Geary
NPI 1285047605
$2,266.92
in general payments reported to CMS, 2019-2025
18 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $652 · 2022: $510 · 2023: $551 · 2024: $362 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $477.44 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $446.77 | 2021-2025 | Xarelto, Spravato |
| Abbvie INC. | $277.10 | 2021-2024 | |
| Glaxosmithkline, LLC. | $181.85 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $156.53 | 2021 | |
| Amgen INC. | $150.34 | 2021-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $90.79 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $83.92 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.30 | 2022-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $75.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.00 | 2021-2022 | |
| Novo Nordisk INC | $38.69 | 2021-2025 | Wegovy |
| Paratek Pharmaceuticals, INC. | $33.27 | 2021-2024 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $33.00 | 2022 | |
| Lilly USA, LLC | $29.45 | 2022-2023 | Mounjaro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $28.55 | 2021-2022 | |
| Esperion Therapeutics, INC. | $17.41 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryna Geary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.